H.C. Wainwright raised the firm’s price target on DBV Technologies (DBVT) to $35 from $20 and keeps a Buy rating on the shares. The firm says its recent conversations with key opinion leaders further support its belief that DBV is positioned to deliver the first broadly accessible epicutaneous immunotherapy for peanut allergies. The VITESSE Phase 3 data is expected in Q4 of this year, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies initiated with an Overweight at Cantor Fitzgerald
- Guggenheim starts DBV Technologies at Buy on peanut allergy market potential
- DBV Technologies initiated with a Buy at Guggenheim
- Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
- DBV Technologies announces last patient visit completed in VITESSE trial